Please provide your email address to receive an email when new articles are posted on . Acute and recurrent pericarditis require medical management to improve morbidity and quality of life. Aspirin, ...

Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p<0.0001) Safety results consistent with FDA-approved label ...

Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes ...

Recurrent pericarditis occurred in one fifth of patients with systemic lupus erythematosus (SLE), with higher recurrence rates observed in younger patients and those receiving oral prednisone therapy.

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful ...

DALLAS, June 17, 2024 — About 40,000 people in the United States experience recurrent pericarditis, or inflammation of the sac-like structure that protects the heart, which can cause chest pain and ...

Credit: Getty Images A discussion on the new American Heart Association’s pericarditis initiative with Jimmy Kerrigan, MD. For the estimated 40,000 adults with recurrent pericarditis in the United ...

Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...

Kiniksa Pharmaceuticals has partnered with country music star Carly Pearce and NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis, a chronic heart condition that is ...

– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...

This is a Designated News Release. Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life ...